AUSTIN, Texas, April 7, 2016 /PRNewswire/ -- Luminex
Corporation (NASDAQ: LMNX) today announced that it will showcase
its recently CE-IVD marked, sample to answer ARIES®
molecular diagnostic system and related assays at the annual
meeting of the European Society of Clinical Microbiology and
Infectious Diseases (ECCMID) taking place in Amsterdam April
9-12. The new ARIES® System headlines a growing
list of featured products from the company for molecular diagnosis
of infectious diseases that are designed to improve result accuracy
outcomes while reducing overall costs.
![ARIES is a sample to answer system crafted to increase laboratory efficiency, produce accurate results, and fit seamlessly into today's lean laboratory environment. ARIES is a sample to answer system crafted to increase laboratory efficiency, produce accurate results, and fit seamlessly into today's lean laboratory environment.](https://photos.prnewswire.com/prnvar/20160406/352457)
Luminex offers a number of assay panels for use with the
ARIES® System, including the CE-IVD marked
ARIES® HSV 1&2 Assay, and GBS and Flu A/B & RSV
Assays available for research use. The
ARIES® System and ARIES® HSV 1&2
Assay received FDA clearance in October
2015 and were subsequently launched in the U.S. market. The
company will also showcase its NxTAG® Respiratory
Pathogen Panel (RPP), which detects 20 clinically relevant viral
and bacterial respiratory pathogens and also recently received both
CE-IVD marking and FDA clearance. Luminex employees will
demonstrate new software called SYNCT™ and other tools in an
"Experience Room" containing the ARIES® System, a
MAGPIX® instrument, and NxTAG RPP plates within the
Luminex booth space (#12) on the trade show floor. SYNCT software
streamlines data analysis and reporting, and is specifically
designed for the needs of molecular labs running ARIES®
or NxTAG RPP assays to allow lab directors to manage their lab data
from multiple workstations through a single interface.
"We are excited to formally introduce the ARIES®
System to more than 10,000 virologists, medical microbiologists,
laboratory directors, and consulting pathologists from Europe and around the world at this important
conference, especially right on the heels of receiving a CE-IVD
mark for the product," said Thomas
Pracht, Managing Director, EMEIA, Luminex Corporation. "We
worked closely with our customers on the design of both our
ARIES® and NxTAG solutions, and initial response has
been extremely favorable. Combined with our other products for
molecular diagnosis of infectious diseases, we are proud to offer a
robust selection of solutions that deliver cost-effective, rapid
results to clinicians and researchers."
To learn more about Luminex technologies featured in the
scientific program at ECCMID, download the full list of
posters.
About the ARIES® System and HSV 1&2
Assay
The ARIES® System is a sample to
answer molecular diagnostic system designed to increase laboratory
efficiency, ensure result accuracy, and fit seamlessly into today's
lean laboratory environment. The ARIES® System uses
internal barcode scanning and other advanced features to minimize
operator errors. Two independent modules each support from one to
six cassettes, allowing for both STAT and Batch testing of IVD and
homebrew assays using MultiCode® Reagents when using a
common Universal Assay Protocol. An integrated touchscreen PC
eliminates the need for a separate computer, standalone keyboard,
and mouse, maximizing valuable bench space.
The ARIES® HSV 1&2 Assay is a real-time
PCR-based qualitative in vitro diagnostic test for the
direct detection and typing of herpes simplex virus (HSV 1&2)
DNA in cutaneous or mucocutaneous lesion specimens from symptomatic
patients, or in cerebrospinal fluid (CSF) from patients suspected
of HSV infections of the central nervous system. The test is
indicated for use with symptomatic individuals to aid in the
diagnosis of HSV infections. The assay is not intended to be used
for prenatal screening. The ARIES® HSV 1&2
Assay is indicated for use on the
ARIES® System.
About NxTAG
The NxTAG Respiratory Pathogen
Panel is CE-marked in Europe, and FDA-cleared in
the U.S. The NxTAG Respiratory Pathogen Panel is an assay
that detects relevant viral and bacterial respiratory pathogens,
including the atypical bacteria Chlamydophila
pneumoniae, Mycoplasma pneumoniae,
and Legionella pneumophila. The panel is the only
respiratory assay that enables laboratories to easily and
simultaneously detect these respiratory pathogens in a single,
closed tube system and in a format that scales to accommodate
changes in throughput needed to respond to seasonal changes in
demand, especially during flu season. The NxTAG Respiratory
Pathogen Panel requires only minutes of hands-on time with no
upstream reagent preparation. The innovative tube strip design
offers laboratories the flexibility to process a single sample or
up to 96 samples per run, without wasting consumables or reagents.
Total turnaround time is only about three hours for 96 samples
(excluding extraction).
About Luminex Corporation
Luminex is committed to
applying its passion for innovation toward creating breakthrough
solutions to improve health and advance science. The company is
transforming global healthcare and life-science research through
the development, manufacturing and marketing of proprietary
instruments and assays utilizing xMAP® open-architecture
multi-analyte platform, MultiCode® real-time polymerase
chain reaction (PCR), and multiplex PCR-based technologies, that
deliver cost-effective rapid results to clinicians and researchers.
Luminex's technology is commercially available worldwide and in use
in leading clinical laboratories, as well as major pharmaceutical,
diagnostic, biotechnology, and life-science companies. Luminex is
meeting the needs of customers in markets as diverse as clinical
diagnostics, pharmaceutical drug discovery, biomedical research
including genomic and proteomic research, personalized medicine,
biodefense research, and food safety. For further information on
Luminex Corporation and the latest advances in multiplexing using
award winning technology, please visit
http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward- looking statements in this release include statements
regarding the development and testing progress of our pipeline
products, and the regulatory approvals thereof. The words
"believe", "expect", "intend", "anticipates", "confident", "will",
"could", "should", and similar expressions are intended to
further identify such forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995. It is
important to note that the Company's actual results or performance
could differ materially from those anticipated in such
forward-looking statements. Factors that could cause Luminex's
actual results or performance to differ materially include risks
and uncertainties relating to, among others, our ability to launch
products on time, the timing of regulatory approvals, the outcome
of clinical trials as well as the risks discussed under the heading
"Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as
filed with the Securities and Exchange Commission. The forward
looking statements contained herein represent the judgment of
Luminex as of the date of this press release, and Luminex expressly
disclaims any intent, obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements to
reflect any change in Luminex's expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based.
Contacts
|
|
Luminex Investor
Contact
|
Luminex Media
Contact
|
Harriss
Currie
|
Christine
Valle
|
Sr. Vice President of
Finance and CFO
|
Sr. Manager, Global
Marketing
|
512.219.8020
|
512.219.8020
|
hcurrie@luminexcorp.com
|
cvalle@luminexcorp.com
|
Photo - http://photos.prnewswire.com/prnh/20160406/352457
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/luminex-corporation-to-showcase-ce-ivd-marked-aries-system-revolutionary-software-and-assays-at-eccmid-annual-meeting-300247637.html
SOURCE Luminex Corporation